Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01603082 · ClinicalTrials.gov registry record · Phase 4

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

A Phase 4 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 4
Development phase
343
Enrollment target

NCT01603082: Completed Phase 4 study, sponsored by AstraZeneca.

NCT01603082 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 343 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01603082, a Phase 4 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 4
Development phase
343 participants
Enrollment target

Study Summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI

Primary Outcome

Participants with low (\<150) baseline PRU values were excluded.

Interventions

  • DRUG Clopidogrel
  • DRUG Ticagrelor

Trial Details

FieldValue
Enrollment Target 343 participants
Start Date 2012-07
Est. Completion 2014-06
Phase Phase 4
AstraZeneca

1,285 total trials

What the finished NCT01603082 record still lists

NCT01603082 is an interventional study that assigns participants to a tested intervention. The registered 343 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (34% lower).

The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.

NCT01603082 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01603082 about?

NCT01603082 is a clinical study titled "Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients". The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI

What is the current status of trial NCT01603082?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 343 participants. The study started on 2012-07. Estimated completion is 2014-06.

What interventions are being tested in trial NCT01603082?

The interventions under investigation include: Clopidogrel (DRUG), Ticagrelor (DRUG).

Who is sponsoring clinical trial NCT01603082?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01603082's enrollment target sits among peer trials

343 246th of 2000 higher than 1,755 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06733363 · 344 participants · Phase 2

    A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

  • NCT07179380 · 344 participants · Phase 3

    Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • NCT07304024 · 344 participants · Phase 1

    A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

  • NCT05283850 · 342 participants · Phase 2

    Surviving PEA in Roanoke (SPEAR) Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01603082, the US trial registry maintained by the National Library of Medicine. NCT01603082 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.